(OAS) of 54% at 15 years. OAS was significantly better in first relapse patients (67%) than in patients with refractory/induction failure (39%) and advance disease (29%) (p=0.002). The major cause of death was progression of HL (32% at 15 years). Treatment related mortality including death from second malignancy was 17% at 15 years. Cumulative risk of a second malignancy was 9% at 15 years. KPS was 90% in 47 patients although hypogonadism (20 patients), hypothyroidism (12), unusual infections (10), anxiety/depression (7), and cardiac disease (5) were not uncommon in survivors. HD-ASCT can lead to durable remissions in relapsed/refractory HL with acceptable but definite late toxicity. The occurrence of late events necessitates lifelong medical surveillance.
INTRODUCTION
High-dose chemotherapy followed by autologous stem cell transplantation (HD-ASCT) is now the accepted therapy for most patients with Hodgkin Lymphoma (HL) that is not controlled by conventional multiagent chemotherapy and can result in long-term progression-free survival (PFS) in a significant proportion of patients. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] HL patients successfully treated with conventional therapy are at greater risk of cardiovascular, pulmonary and endocrine dysfunction, may be unusually susceptible to infection and appear to have an increased incidence of second malignancy. [12] [13] [14] [15] [16] Less is known about the incidence of late complications in survivors of HD-ASCT for HL. Beginning in 1985, patients with HL at our institution who either failed to enter complete remission or progressed after multiagent chemotherapy were routinely referred for HD-ASCT. In order to determine prognostic factors for a successful outcome and to better define long-term complications, data were collected and analyzed on the first 100 patients who underwent HD-ASCT for HL in Vancouver.
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PATIENTS AND METHODS

Patient characteristics
Between March 1985 and June 1992, 100 patients with HL were enrolled on a HD-ASCT protocol approved by the Institutional Review Boards of the British Columbia Cancer Agency, Vancouver General Hospital and the University of British Columbia. All patients provided written informed consent. Patient characteristics for the entire group are shown in Table 1 . All patients in this study have previously been included in one or more published reports from our centre. 8, 9, 20 To be eligible for HD-ASCT, patients had to have either failed to enter a complete remission or progressed after conventional multiagent chemotherapy. Patients with localized nodal recurrences considered potentially curable with extended field radiotherapy were specifically excluded from enrolment. 17 To proceed to HD-ASCT, patients had to be 60 years of age and had to have adequate cardiac, pulmonary, hepatic and renal function.
Conventional cytoreduction prior to HD-ASCT
Patients that had not received conventional chemotherapy during the previous three months, were routinely given two cycles of MVPP (mechlorethamine, vinblastine, procarbazine and prednisone) 18 to allow time to arrange for a transplant bed. Those who had received more recent chemotherapy and in whom systemic disease was not rapidly progressing, proceeded directly to HD-ASCT. In addition, all patients with bulky disease (nodal masses > 5 cm or mediastinal disease greater than 1/3 of the transthoracic diameter) or disease easily encompassed within a single, previously untreated field, received local radiotherapy prior to HD-ASCT.
Disease status
Disease status was determined at protocol entry, not at the time of HD-ASCT. Patients were not formally restaged after conventional cytoreductive therapy and all patients enrolled went on to
For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From HD-ASCT. Patients in first relapse (REL1) were distinguished from primary refractory/induction failure (IF) patients, by the requirement for a period of at least three months without disease progression following completion of first-line chemotherapy. In order to proceed to HD-ASCT, IF patients were required to have persistent or progressive HL after primary chemotherapy as determined by either a tissue biopsy or unequivocal diagnostic imaging. Patients in second or subsequent relapse were grouped together as having advanced disease (AD). Characteristics specific to REL1 patients are shown in Table 2 .
Conditioning and supportive care
The first 29 patients received high-dose intravenous cyclophosphamide 1.8g/m ] as previously described. 19 Supportive care was standardized but did vary over time according to institutional policy. 8, 9, 19, 20 After HD-ASCT, all patients were advised to have an influenza vaccination annually, a pneumococcal vaccination every five years and a diptheria/tetanus vaccination every ten years.
Stem cell transplantation
Most patients received unmanipulated, cryopreserved autologous bone marrow (n=91).
Patients who had active marrow involvement with HL initially underwent "steady-state" blood stem cell collections (i.e. without growth factor mobilisation) (n=3 
Data collection
The date of HD-ASCT was considered day 0 and follow-up was to the date of last medical examination. Standard follow-up consisted of complete blood counts, serum creatinine, alkaline phosphatase, bilirubin and thyroid stimulating hormone (TSH); physical examination and chest radiograph; and additional imaging studies as warranted by symptoms. Determination of remission status and cause of death and monitoring for the occurrence of a second malignancy or other late complication was performed by reviewing charts, medical correspondence, death certificates and autopsy information, when available. Most survivors were still being seen annually by their physician but if medical follow-up was lacking, the patient was contacted and asked to answer a standardized health questionnaire. All 53 survivors were located and patients [29% (CI 11-51%)] (p=0.016). For these subgroups, the actuarial risks of TRM were 12%, 13% and 41%, respectively (p=0.008) and the actuarial risks of relapse were 27%, 48% and 29%, respectively (p=0.16).
Performance status
Most survivors (47 patients, 89%) have a KPS 90% and have been able to return to normal activity levels. However, four patients remain on full disability and one patient is on partial disability.
Treatment-Related Mortality (TRM)
Deaths attributable to TRM included eight deaths prior to day +100 (pulmonary toxicity in 3 patients, cardiac toxicity in 3 patients and sepsis in 2 patients), six deaths (between day +133 and day +1567) from delayed lung toxicity and four deaths from second malignancies. 
Progression of HL post-HD-ASCT
Progression of HL was detected in 32 patients at a median of 7.9 months (range 0.1-7.7 years) post-HD-ASCT. Progression occurred during the first two years in 22 of these patients (72%); however, three patients relapsed more than four years following HD-ASCT (4.1, 4.8 and 7.7 years). The majority of patients with progression of HL received palliative chemo/radiotherapy after which median survival was 7.3 (range 0.1-72.0) months. Four patients with localized recurrences after HD-ASCT in sites not previously irradiated have been in a continuous CR of more than ten years following salvage radiotherapy.
Prognostic factors for PFS
Univariate analysis using the entire cohort identified number of prior chemotherapy regimens (1 vs 2) (p=0.0002) and disease status at HD-ASCT (p=0.02) as predictive of PFS (Table 3) . In multivariate analysis, more than one prior chemotherapy regimen was the only independent risk factor (p=0.0002). Since disease status was significant in univariate analysis, a subset analysis was performed on REL1 patients. Univariate analysis in this subgroup demonstrated that more than one prior chemotherapy regimen (p=0.006), extranodal disease at relapse (p=0.005), use of blood stem cells (p=0.04) and B symptoms at relapse (p=0.04) were all risk factors for inferior PFS. The corresponding multivariate model confirmed that more than one prior chemotherapy regimen (p=0.004) and extranodal disease at relapse (p=0.009) were independent risk factors ( Table 3) .
Second malignancy
Seven patients developed second malignancies [myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML) two patients; glioblastoma, renal cell carcinoma (Ca) 
Endocrine deficiencies
Of the surviving patients, twenty (38%) were on hormone replacement therapy for hypogonadism (female, n=18; male, n=2). However, five females who underwent HD-ASCT at age 18-27 years, successfully conceived and delivered a total of ten healthy children. None of the men reported fathering children after HD-ASCT. Twelve patients (23%) were on thyroid replacement and all had received prior neck irradiation. Three patients experienced avascular necrosis of the femoral head, with two requiring total hip replacement, and a fourth patient was placed on a biphosphonate for osteoporosis after suffering a wrist fracture.
Other complications
Two patients reported long-standing and debilitating lymphedema in the lower extremities from prior lymph node biopsy or pelvic irradiation. Seven patients reported significant anxiety/depression within the previous five years and four patients had developed a substance abuse disorder.
For
DISCUSSION
This report involves a minimum ten year follow-up of a large single institution cohort of primary refractory or relapsed HL patients that underwent HD-ASCT. The study findings indicate that HD-ASCT can lead to durable remissions and that the vast majority of survivors have a satisfactory performance status. The early TRM (prior to day +100) of 8% is consistent with what was commonly observed at transplant centres more than a decade ago. With better patient selection, improved supportive care and the introduction of blood stem cells, the early TRM associated with HD-ASCT has decreased to less than 5%. 2, 3, 24, 25 With this in mind, the remaining limitations of HD-ASCT for HL are disease recurrence and late complications.
A 15-year OAS of 67% and PFS of 62% for REL1 patients has been demonstrated in our study cohort. This result is particularly gratifying as it was unlikely to have been influenced by patient selection. The treatment approach was applied in a standard fashion for all patients in British
Columbia during the time period of the study and chemosensitivity was not a prerequisite for proceeding to HD-ASCT. It should also be noted that patients expected to have a favourable outcome with salvage radiotherapy alone were excluded from the study. 17, 26 A previous analysis indicated that CR1 duration of less than 12 months, B symptoms or extranodal disease at relapse were all independent predictors of decreased PFS for REL1
patients. 2 The current univariate analysis confirmed the significance of the latter two factors but, in multivariate analysis, extranodal disease at relapse and number of prior chemotherapy regimens were the only independent risk factors identified. Since our results demonstrate that disease status and number of prior chemotherapy regimens are predictive of outcome, early consideration of HD-ASCT should optimize PFS for HL patients failing conventional chemotherapy.
The 15-year PFS of 39% for primary refractory HL patients after HD-ASCT is consistent with results reported by other groups. 4, 5 While these patients have an increased risk of relapse following HD-ASCT compared to REL1 patients, the highest risk period for disease progression is early and survival is well-maintained beyond the first year.
In our experience, relapse was the primary contributor to an unsuccessful outcome after HD-ASCT and can occur up to eight years after HD-ASCT, as has previously been described. 27 Patients that relapse after HD-ASCT are usually treated palliatively but, it is noteworthy that four of our patients with a localised recurrence became long-term survivors following limited radiotherapy. This would suggest that some patients with HL resistant to HD-ASCT may show selective radiosensitivity and that localized relapses in an area not previously irradiated may still be treated with curative intent.
The most common cause of death in our patient cohort aside from progression of HL, was pulmonary toxicity. Interstitial pneumonitis after HD-ASCT appears to be related to the use of either high-dose Carmustine (BCNU) or total body irradiation in the conditioning regimen. 8, 9, 18, 19 During the study period, the CVP regimen was modified by the addition of cisplatin (CBVP) and reduction in the BCNU dose from 600 mg/m 2 to 500 mg/m 2 . These modifications did result in less mucosal and hepatic toxicity but did not reduce the incidence of pulmonary toxicity (24% vs. 21%, p=0.98). Furthermore, the treatment-related mortality (26% vs. 23%, p=0.40) and the risk of relapse (43% vs. 36%, p=0.62) were not significantly different between the two conditioning regimens. 19 However, in recent years, the management of patients with suspected BCNU lung toxicity at our centre has become more aggressive, with prompt institution of highdose corticosteroids at the first sign of dyspnea.
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With the decline in early TRM, greater interest has focused on late complications of HD-ASCT.
Unfortunately, few studies have adequate long-term follow-up to address this issue in HL patients but HD-ASCT survivors may be at risk for second malignancies. [28] [29] [30] [31] French registry data were used to compare the incidence of second malignancy in HL patients treated with HD-ASCT with a conventionally treated cohort. 32 The actuarial risk of developing any second cancer at five years was 8.9% after HD-ASCT, with the incidence of solid tumours being significantly higher than after conventional therapy (RR=5.19, p=0.001). The incidence of MDS/AML was similar in both patient cohorts suggesting that this disorder may result from exposure to alkylating agents prior to HD-ASCT. In contrast to the French data, a recent comparative analysis done at our institution concluded that the risk of any second malignancy in HD patients having had HD-ASCT is the same as that observed in a large cohort of patients treated with conventional chemotherapy alone. 33 Although our study attempted to identify late adverse effects attributable to the HD-ASCT protocol, it did not involve prospective, systematic evaluation of major organ function. It is quite likely that our retrospective analysis underestimated the incidence of long-term complications following HD-ASCT. Many of the long-term complications seen in our study (cardiac and pulmonary disease, late infections, endocrine dysfunction, avascular necrosis and psychological problems) have previously been described following conventional treatment for HL. [12] [13] [14] [15] [16] [34] [35] [36] Mediastinal irradiation is thought to be responsible for damage to the coronary arteries and other structures of the heart that has been seen in conventionally-treated HL patients 34, 35 and mortality from heart disease in this patient population is exceeded only by mortality due to progression of HL or the development of a second neoplasm. [12] [13] [14] [15] [16] Four of the five patients in
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Hypothyroidism is uncommon in HL patients not having received neck irradiation, which is known to increase the 20-year risk to 30-50%. 36 All of the patients on thyroid replacement in our study had received neck irradiation and it seems unlikely that the HD-ASCT was responsible for this complication. While the HD-ASCT may have contributed to its development, gonadal dysfunction is almost universal in men treated with MOPP or MVPP and half the women similarly treated will have persistent amenorrhea. Avascular necrosis is a well-known complication of high-dose glucocorticoid therapy implicating MOPP and/or MVPP as the probable cause of the three cases observed in our analysis.
Unusual and/or recurrent infections occurring more than five years after HD-ASCT were reported by 10% of our survivors. Serious late infections, although rare, do occur after HD-ASCT and, even after conventional chemotherapy, 37 immunoreconstitution can be delayed in HL patients. Although seven patients had previously undergone splenectomy during initial disease staging, this did not appear to contribute to the development of late infections. As recommended to our patients, a regular immunization schedule may be useful in protecting survivors from common community-acquired pathogens and should be incorporated into longterm care of all HL patients, including those who have undergone HD-ASCT.
Although most HD-ASCT survivors in the current study were leading a normal life at the time of their last medical evaluation, long-lasting psychological problems were observed. This is not unexpected in light of the physical and emotional trauma associated with developing cancer, receiving chemoradiotherapy and coping with the fear of relapse. 38, 39 Preservation of fertility is an important issue for young patients with HL and we were able to confirm that young women
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From treated with non-TBI conditioning regimens, particularly those undergoing HD-ASCT prior to age 30 years, may still be able to conceive following HD-ASCT. 24 In conclusion, it is now clear that HD-ASCT leads to a durable remission in the majority of patients and that most survivors have an excellent performance status. However, with longer follow-up, late relapses are seen and second malignancies and infectious, cardiac, endocrine and psychological complications do occur in a significant proportion of patients. Reporting late complications after HD-ASCT is important to ensure awareness in physicians and patients so that clinical follow-up can be maintained and appropriate screening and intervention programs devised.
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